This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.02696-06v1 81/9/4654    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abbink, P. Articles by Barouch, D. H. Search for Related Content PubMed PubMed Citation Articles by Abbink, P. Articles by Barouch, D. H.

 Previous Article  |  Next Article 

Journal of Virology, May 2007, p. 4654-4663, Vol. 81, No. 9
0022-538X/07/$08.00+0     doi:10.1128/JVI.02696-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215,¹ Crucell Holland BV, 2301 CA, Leiden, The Netherlands,² New England Primate Research Center, Southborough, Massachusetts 01772³

Received 6 December 2006/ Accepted 17 February 2007

Recombinant adenovirus serotype 5 (rAd5) vector-based vaccines are currently being developed for both human immunodeficiency virus type 1 and other pathogens. The potential limitations associated with rAd5 vectors, however, have led to the construction of novel rAd vectors derived from rare Ad serotypes. Several rare serotype rAd vectors have already been described, but a detailed comparison of multiple rAd vectors from subgroups B and D has not previously been reported. Such a comparison is critical for selecting optimal rAd vectors for advancement into clinical trials. Here we describe the construction of three novel rAd vector systems from Ad26, Ad48, and Ad50. We report comparative seroprevalence and immunogenicity studies involving rAd11, rAd35, and rAd50 vectors from subgroup B; rAd26, rAd48, and rAd49 vectors from subgroup D; and rAd5 vectors from subgroup C. All six rAd vectors from subgroups B and D exhibited low seroprevalence in a cohort of 200 individuals from sub-Saharan Africa, and they elicited Gag-specific cellular immune responses in mice both with and without preexisting anti-Ad5 immunity. The rAd vectors from subgroup D were also evaluated using rhesus monkeys and were shown to be immunogenic after a single injection. The rAd26 vectors proved the most immunogenic among the rare serotype rAd vectors studied, although all rare serotype rAd vectors were still less potent than rAd5 vectors in the absence of anti-Ad5 immunity. These studies substantially expand the portfolio of rare serotype rAd vectors that may prove useful as vaccine vectors for the developing world.

Published ahead of print on 28 February 2007.

This article has been cited by other articles:

• Kaufman, D. R., Liu, J., Carville, A., Mansfield, K. G., Havenga, M. J. E., Goudsmit, J., Barouch, D. H. (2008). Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination. J. Immunol. 181: 4188-4198 [Abstract] [Full Text]  
• Kaufman, D. R., Goudsmit, J., Holterman, L., Ewald, B. A., Denholtz, M., Devoy, C., Giri, A., Grandpre, L. E., Heraud, J.-M., Franchini, G., Seaman, M. S., Havenga, M. J. E., Barouch, D. H. (2008). Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice. J. Virol. 82: 6829-6837 [Abstract] [Full Text]  
• Liu, J., Ewald, B. A., Lynch, D. M., Denholtz, M., Abbink, P., Lemckert, A. A. C., Carville, A., Mansfield, K. G., Havenga, M. J., Goudsmit, J., Barouch, D. H. (2008). Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys. J. Virol. 82: 4844-4852 [Abstract] [Full Text]  
• Schoenly, K. A., Weiner, D. B. (2008). Human Immunodeficiency Virus Type 1 Vaccine Development: Recent Advances in the Cytotoxic T-Lymphocyte Platform "Spotty Business". J. Virol. 82: 3166-3180 [Full Text]  
• Rodriguez, A., Goudsmit, J., Companjen, A., Mintardjo, R., Gillissen, G., Tax, D., Sijtsma, J., Weverling, G. J., Holterman, L., Lanar, D. E., Havenga, M. J. E., Radosevic, K. (2008). Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1. Infect. Immun. 76: 1709-1718 [Abstract] [Full Text]